Veracyte Inc
General ticker "VCYT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.3B
Veracyte Inc follows the US Stock Market performance with the rate: 58.0%.
Estimated limits based on current volatility of 3.4%: low 38.85$, high 41.56$
Factors to consider:
- US accounted for 92.7% of revenue in the fiscal year ended 2023-12-31
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [23.43$, 40.55$]
- 2024-12-30 to 2025-12-30 estimated range: [24.76$, 42.62$]
Financial Metrics affecting the VCYT estimates:
- Negative: Non-GAAP EPS, $ of -0.30 <= 0.10
- Negative: Operating profit margin, % of -19.20 <= 1.03
- Negative: negative Net income
- Positive: Inventory ratio change, % of -0.03 <= 0
- Negative: Operating cash flow per share per price, % of 2.28 <= 2.35
- Positive: Investing cash flow per share, $ of 0.21 > -0.12
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VCYT quotes
Long-term VCYT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $219.51MM | $296.54MM | $361.05MM |
| Operating Expenses | $301.42MM | $337.62MM | $446.85MM |
| Operating Income | $-81.90MM | $-41.08MM | $-85.80MM |
| Non-Operating Income | $0.25MM | $4.65MM | $9.18MM |
| Interest Expense | $0.24MM | $0.20MM | $0.01MM |
| R&D Expense | $29.84MM | $40.60MM | $57.30MM |
| Income(Loss) | $-81.65MM | $-36.43MM | $-76.61MM |
| Taxes | $-6.09MM | $0.13MM | $-2.21MM |
| Profit(Loss) | $-75.56MM | $-36.56MM | $-74.40MM |
| Stockholders Equity | $1,096.51MM | $1,075.20MM | $1,044.10MM |
| Inventory | $11.22MM | $14.29MM | $16.13MM |
| Assets | $1,187.83MM | $1,156.42MM | $1,114.91MM |
| Operating Cash Flow | $-31.62MM | $7.54MM | $44.22MM |
| Capital expenditure | $5.38MM | $8.55MM | $9.96MM |
| Investing Cash Flow | $-739.21MM | $-29.39MM | $15.11MM |
| Financing Cash Flow | $596.32MM | $3.49MM | $2.84MM |
| Earnings Per Share* | $-1.11 | $-0.51 | $-1.02 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.